dshah
★★  

India/United Kingdom,
2022-03-30 19:09
(357 d 07:26 ago)

(edited by dshah on 2022-03-31 11:42)
Posting: # 22889
Views: 997
 

 Bempedoic Acid TBM BE study in SBOA [BE/BA News]

Post reply
Hello All!

I was going through SBOA of Bempedoic acid marketed as Nexleton tablets.
In general, a BE study of Phase III vs TBM formulation can suffice the need for clinical significance. But in what condition, FDA can waive such condition of BE of TBM formulation with Phase III formulations in IND filing? [image]
or considering the biopharmaceutics risk assessment- it is a low risk and study can be waived?
[image]
Regards,
Divyen Shah
 
jag009
★★★

NJ,
2022-03-31 10:43
(356 d 15:52 ago)

@ dshah
Posting: # 22890
Views: 864
 

 Bempedoic Acid TBM BE study in SBOA

Post reply
Hi,
I heard from a change in the shape of the tablet will raise question as well.
J
 
UA Flag
Activity
 Admin contact
22,548 posts in 4,723 threads, 1,606 registered users;
29 visitors (0 registered, 29 guests [including 14 identified bots]).
Forum time: 01:35 CET (Europe/Vienna)

You can’t really say “similar” if it’s the same again you want.
“Similar” means something different.    Anthony Burgess

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5